Advertisement
Matrix Laboratories
Premium
General
29 February, 2024
Grapevine: KKR mulls JB Pharma sale; Bharti eyes Del Monte JV exit
Private equity firm KKR & Co. is exploring options for a potential sale of its 53.8% controlling stake in Mumbai-based ......
Premium
Healthcare
03 January, 2024
Kotak's second special situations PE fund bankrolling big-ticket pharma acquisition
Kotak Alternate Asset Managers (previously Kotak Investment Advisors), the alternative investment arm of Kotak Group, which hit a first close of ......
Premium
Healthcare
04 September, 2017
Company watch: Concord Biotech eyes new opportunities after Quadria's backing
Biotechnologist Sudhir Vaid quit drugmaker Ranbaxy Laboratories Ltd exactly 20 years ago to start his entrepreneurial journey. The Ahmedabad-based biotechnology ......
Advertisement
Recommended for you
Advertisement